Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to Sell at Wall Street Zen

Key Points

• Voyager Therapeutics was downgraded by Wall Street Zen from hold to sell, adding to mixed analyst sentiment around the stock.
• The company reported a smaller-than-expected quarterly loss of ($0.47) EPS, but revenue of $1.19 million fell well short of analyst expectations.
• VYGR shares were up 2.3% to $4.05, while the stock remains a small-cap biotech with a negative earnings profile and notable insider selling in recent months.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday.

A number of other research analysts have also recently commented on the company. Truist Financial raised Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 25th. HC Wainwright reissued a "buy" rating and issued a $25.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, March 17th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Voyager Therapeutics in a research note on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $16.50.

Voyager Therapeutics Stock Up 2.3%

VYGR opened at $4.05 on Friday. The stock has a market cap of $244.70 million, a PE ratio of -2.06 and a beta of 1.26. Voyager Therapeutics has a 52 week low of $2.64 and a 52 week high of $5.55. The business's fifty day simple moving average is $4.04 and its 200 day simple moving average is $4.06.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $1.19 million for the quarter, compared to analysts' expectations of $8.79 million. Voyager Therapeutics had a negative return on equity of 53.03% and a negative net margin of 319.61%. As a group, equities analysts anticipate that Voyager Therapeutics will post -1.73 earnings per share for the current year.

Insider Activity

In other news, CEO Alfred Sandrock sold 14,197 shares of the firm's stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the transaction, the chief executive officer directly owned 484,060 shares of the company's stock, valued at approximately $1,834,587.40. This trade represents a 2.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 61,294 shares of company stock worth $233,241 over the last quarter. 6.39% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Wexford Capital LP bought a new position in shares of Voyager Therapeutics during the third quarter valued at about $42,000. ProShare Advisors LLC bought a new position in shares of Voyager Therapeutics during the fourth quarter valued at about $44,000. CIBC Asset Management Inc bought a new position in shares of Voyager Therapeutics during the fourth quarter valued at about $45,000. Coldstream Capital Management Inc. bought a new position in shares of Voyager Therapeutics during the third quarter valued at about $55,000. Finally, EHP Funds Inc. bought a new position in shares of Voyager Therapeutics during the third quarter valued at about $58,000. 48.03% of the stock is owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.